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The homotrimericHIV-1 envelope glycoprotein (Env) under-
goes receptor-triggered structural changes that mediate viral
entry through membrane fusion. This process is inhibited by
chemokine receptor antagonists (CoRAs) that block Env–
receptor interactions and by fusion inhibitors (FIs) that disrupt
Env conformational transitions. Synergy between CoRAs and
FIs has been attributed to a CoRA-dependent decrease in the
rate of viral membrane fusion that extends the lifetime of the
intermediate state targeted by FIs. Here, we demonstrated that
the magnitude of CoRA/FI synergy unexpectedly depends on
FI-binding affinity and the stoichiometry of chemokine receptor
binding to trimeric Env. For C-peptide FIs (clinically repre-
sented by enfuvirtide), synergy waned as binding strength
decreased until inhibitor combinations behaved additively.
Curiously, this affinity dependence on synergy was absent for
5-Helix-type FIs. We linked this complex behavior to the CoRA
dependence of Env deactivation following FI binding. For both
FI classes, reducing chemokine receptor levels on target cells or
eliminating competent chemokine receptor-binding sites on
Env trimers resulted in a loss of synergistic activity. These data
imply that the stoichiometry required for CoRA/FI synergy
exceeds that required forHIV-1 entry.Our analysis suggests two
distinct roles for chemokine receptor binding, one to trigger
formation of the FI-sensitive intermediate state and another to
facilitate subsequent conformational transitions. Together, our
results could explain the wide variety of previously reported
activities for CoRA/FI combinations. These findings also have
implications for the combined use of CoRAs and FIs in antiviral
therapies and point to a multifaceted role for chemokine recep-
tor binding in promoting HIV-1 entry.
The envelope glycoprotein (Env)2 of human immunodefi-
ciency virus-type 1 (HIV-1) is composed of gp120 and gp41
subunits arranged as a trimer of heterodimers in the viralmem-
brane (1). It is formed through trimerization in the endoplasmic
reticulum of precursor protein gp160, which is subsequently
cleaved into a surface (gp120) and transmembrane (gp41) subunit
that remain noncovalently associated. The three gp120 subunits
form a canopy that cradles a trimeric gp41 core and locks the
transmembrane protein in a metastable conformation (2–4).
Trimerization is stabilized through gp120–gp120 interactions
involving theV1/V2 andV3 variable loops at the apex of the com-
plex and through a coiled coil formed by part of an N-terminal
heptad repeat (N-HR) in the gp41 ectodomain (5–7).
Env undergoes receptor-triggered conformational changes
to promoteHIV-1 entry throughmembrane fusion (8–10). The
gp120 subunits interactwith cellularCD4, altering the Env apex
to release constraints on theV3 loops. The releasedV3 loop and
an additional newly formed gp120 element (bridging sheet) can
now interact with a chemokine receptor, typically CCR5 or
CXCR4 (collectively referred to as the coreceptor) (11–15).
Receptor interactions also alter the gp120/gp41 interface and
coordinate a complex series of structural changes in the trans-
membrane subunit (8, 9). First, each gp41 extends to insert its
N-terminal fusion peptide segment into the target cell mem-
brane. During this intermediate state (denoted the prehairpin
intermediate or PHI), the N-HR coiled coil and an additional
heptad repeat segment at the C terminus of the gp41 ectodo-
main (C-HR) become transiently exposed to the extracellular
environment (16–20). Driven by a strong affinity for one
another, the N-HR coiled coil associates with the three C-HR
domains to form a compact trimer-of-hairpins (TOH) (21, 22).
Collapse into the TOH juxtaposes the fusion peptides, trans-
membrane regions, and their associated membranes in a man-
ner required for viral membrane fusion (10).
Molecules that block Env interactions with cellular receptors
or disrupt Env conformational changes can effectively inhibit
HIV-1 entry (23). Two classes of such molecules are currently
used in the clinic. The first, denoted coreceptor antagonists
(CoRAs), binds to the extracellular loops and transmembrane
helices of CXCR4 or CCR5, blocking their interaction with the
V3 loop of gp120 (24). The second, denoted fusion inhibitors
(FIs), binds to the gp41 N-HR coiled coil or C-HR segments,
blocking their ability to form the TOH (25–30). The clinically
approved drugs maraviroc (CoRA) and enfuvirtide (FI, also
denoted T20) are currently employed as second line therapy
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and used when traditional highly active antiretroviral therapy
(HAART) becomes ineffective (31–34).
Based on their mechanisms of action, CoRAs and FIs should
display synergistic activity when used in combination. Because
the gp41 N-HR and C-HR are only transiently exposed during
the PHI, FI potency depends on kinetics of inhibitor binding
and Env dynamics (16, 17, 19, 35–39). An important determi-
nant of FI activity is the lifetime of the PHI, a property that
critically depends on Env interactions with chemokine recep-
tors. Reducing either coreceptor levels on target cells or their
binding affinity for gp120 decreases the rate of Env-mediated
membrane fusion, prolonging the lifetime of the PHI (19, 35,
38–42). Because FIs have more time to bind gp41 during this
prolonged PHI, their potency is enhanced. Theoretically,
CoRAs should have the same functional effect as reducing core-
ceptor levels on target cells.
Surprisingly, studies of CoRA/FI combinations have pro-
duced inconsistent results. Although some reports have shown
strong synergy between FIs and CoRAs (or coreceptor-binding
proteins such as RANTES (regulated on activation normal T
cell expressed and secreted) or monoclonal antibodies) (43–
45), a number of studies have revealed only weak synergy or
additivity between these two inhibitor classes (31, 45, 46). In
one study exploring combinations of CoRA SCH-C and T20 on
activated peripheral blood mononuclear cells (PBMCs), three
of six CCR5-tropic clinical HIV-1 isolates showed little or no
synergy at all inhibitor concentrations, whereas the others
showed strongly dose-dependent synergy (47). Here, we inves-
tigated the origins of this variability by exploring the inhibitory
properties of different CoRA/FI combinations against different
Env variants. Our findings revealed that the mechanism of syn-
ergy is more complex than originally postulated. We showed
that the degree of CoRA/FI synergy strongly depends on FI-
binding affinity and on coreceptor-Env binding stoichiometry.
The results have implications for the effectiveness of clinical
therapies involving CoRA/FI combinations and for the role of
coreceptor binding in coordinating Env structural changes dur-
ing HIV-1 entry.
Results
Measurement of synergy between FIs and CoRAs
There are a number of strategies to quantify the synergistic,
additive, or antagonistic properties of inhibitor combinations
(48–50). In this study, we focused specifically on the impact of
CoRAs on the inhibitory potency of FIs.Our strategy is outlined
in Fig. 1, A and C–E, on data obtained using inhibitors maravi-
roc and T20. HIV-1 pseudotyped with primary isolate EnvJR-FL
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Figure 1. Combinatorial activities of CoRAmaraviroc and FIs T20 and 5-Helix against EnvJR-FL. A,maraviroc titration of HIV-1 infection in the absence of
FIs. Data have been normalized to the infection level in the absence of inhibitor. Data at maraviroc concentrations 0.5 (red), 1 (green), 2 (dark blue), and 4 nM
(cyan) have been highlighted as these concentrations were used for combinatorial studies. The measured IC50 value is 0.45 0.15 nM. B, schematic of gp41
depicting the relative positions of the fusion peptide (FP), N-HR, C-HR, and transmembrane (TM) segments of the ectodomain. Binding sites for T20 and 5-Helix
are designated. C, titration of T20 in the absence (black) and presence of maraviroc (colored as in A). Data have been normalized to the infection level in the
absence of either entry inhibitor.D, T20 titrations shown in C renormalized to the level of infection in the absence of T20 and the presence ofmaraviroc (if any).
E,plot of IC50 for T20 inhibition as a function ofmaraviroc concentration. IC50 valueswere determined from the titration curves shown inD. F–H,data for 5-Helix
inhibition displayed as described in C–E. Data points and error bars represent themean S.E. of three ormore independent experiments. Titrations have been
fit (solid lines) with a simple dose-response equation to extract IC50 values (see Equation 1).
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was utilized to infect U87-CD4-CCR5 target cells. The IC50
(IC50 indicates 50% inhibitory concentration) value for maravi-
roc in the absence of FI was first determined through careful
titrations to be 0.45 nM (Fig. 1A). FI titrations were subse-
quently performed in the absence or presence of maraviroc at
various concentrations (0.5, 1, and 2 nM, Fig. 1C). All titrations
were fit to a simple dose–response relationship (Langmuir
equation, see below) to extract IC50 values. To best appreciate
the impact ofmaraviroc onFI potency,we renormalized each FI
titration to the level of infection obtained in the absence of FI
(Fig. 1D). The leftward shift of these renormalized curves in
the presence of CoRA indicates an increase in T20 potency
with increasing maraviroc concentrations. T20 IC50 values
decreased from 35 to 2 nM as the maraviroc concentration was
raised from 0 to 2 nM, reflecting a 17-fold improvement in FI
potency (Fig. 1E).
The decrease in the FI IC50 value as CoRA concentration
increases is a direct measure of synergistic activity. To
appreciate this reasoning, assume that maraviroc and the FIs
displayed additive activity. The probability of viral entry
(Pentry) in the presence of a single inhibitor can be modeled
as shown in Equation 1.
Pentry 
1
1
[inhibitor]
IC50 (inhibitor)
(Eq. 1)
For inhibitors that do not compete for the same site, additive
combinatorial activity can be modeled as the product of indi-
vidual entry probabilities as shown in Equation 2.
Pentry 
1
1
CoRA
IC50 CoRA

1
1 
FI
IC50 (FI)
(Eq. 2)
Under additive interactions, the presence of CoRA will only
impact the scale of FI titrations but not their IC50 values.Hence,
renormalized FI titrations (e.g. Fig. 1D) should overlap, and the
FI IC50 versus CoRA concentration plot (e.g. Fig. 1E) should be
horizontal. However, if the two inhibitors interact synergisti-
cally, then the IC50 values of the normalized FI titrations will be
less in the presence than in the absence of CoRA (as observed).
Conversely, if the two inhibitors interacted antagonistically,
then the IC50 values of the normalized FI titrations will be
greater in the presence than in the absence of CoRA. The anal-
ysis employed here shares a common logic with the calculation
of combination indices developed by Chou and Talalay and
routinely used to quantify drug combinatorial properties (48).
Expanding the product in Equation 2 yields Equation 3.
Pentry 
1
1
[CoRA]
IC50 (CoRA)

[FI]
IC50 (FI)

[CoRA]  [FI]
IC50 (CoRA)  IC50 (FI)
(Eq. 3)
The last three terms of the denominator are equivalent to the
value of the combination index at 50% inhibition for mutually
nonexclusive inhibitors.
FI T20 is an example of a C-peptide, so named because they
are derived from the gp41 C-HR segment. C-peptides block
entry by binding to the gp41 N-HR coiled coil exposed in the
PHI (17, 20, 27, 51). We next asked whether FIs that work in a
complementary manner by targeting gp41 C-HR region would
show similar synergistic activity with CoRAs. We used 5-Helix
(5HWT), an engineered protein containing three N-HR seg-
ments and two C-HR segments alternately connected through
short Gly/Ser linkers (28). When properly folded, 5HWT
exposes a single high-affinity site that binds the gp41 C-HR
region during the PHI. Like T20, 5HWT showed significantly
improved inhibitory activity in the presence of maraviroc (Fig.
1, F–H). However, we did observe considerable differences
between the two FIs. First, the magnitude of synergy for 5HWT
was substantially less, with IC50 falling from 83 to 15 nM (a
5.5-fold change) when the maraviroc concentration was raised
from0 to 4 nM. Second, T20 activitywasmuchmore sensitive to
maraviroc concentration than 5HWT activity; the impact on
T20 potency appeared to saturate at	1 nMmaraviroc, whereas
the impact on 5HWT potency did not saturate in the studied
maraviroc concentration range. The differences likely reflect an
asymmetry in exposure of the gp41 N-HR and C-HR regions
and/or differences in the determinants of potency for FIs that
target these sites (36, 38).
Dependence of C-peptide FI/CoRA synergy on C-peptide-
binding affinity
As a potential source of variability in reported inhibitor com-
bination studies, we asked whether the properties of CoRA/FI
synergy were altered in the presence of Env mutations that dis-
rupt FI-binding affinity. In these experiments, we used HIV-1
pseudotyped with CXCR4-tropic EnvHXB2, U87-CD4-CXCR4
target cells, and CoRAAMD3100. The FI was C37, a well-char-
acterized C-peptide with a binding site that overlaps that for
T20 (38, 52). As with maraviroc/T20 combinations in Fig. 1,
C37 IC50 decreased from 2.8 to 0.37 nM (7.4-fold) as AMD3100
concentration was increased from 0 to 100 nM (Fig. 2C). We
next analyzed a mutant Env variant containing the V549E sub-
stitution known to disrupt C37-binding affinity by 5000-fold
and reduce C37 inhibitory potency by 100-fold (Table 1) (38,
53). The mutation did not alter the potency of AMD3100 (IC50
	26 nM), implying that the V549E substitution did not affect
Env utilization of the coreceptor (Fig. 2B). By contrast, the
mutation ablated synergistic activity between AMD3100 and
C37 observed for wild-type Env (Fig. 2, C and D); C37 IC50
values for theV549EEnv variant in the presence of 0 and 100nM
AMD3100 were essentially identical (	200 nM). The data sug-
gested that AMD3100/C37 combinatorial activity was influ-
enced by FI-binding affinity.
To confirm the importance of binding affinity on the magni-
tude of CoRA/FI synergy, we studied the combinatorial activi-
ties of AMD3100 andmutant C37 variants with altered binding
affinity. We first explored the inhibitory properties of two
mutant C37 variants with lower binding affinities, C37W628A
(50-fold lower affinity) and C37N656D (4000-fold lower) (38).
Consistent with their reduced binding affinities, the mutant
C37 variants displayed lower potency against wild-type Env
(Table 1 and Fig. 3A). Moreover, they also showed significantly
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reduced synergistic activities in combination with AMD3100.
ForC37W628A, FI IC50 improved only 2.5-fold in the presence of
high concentrations of AMD3100 (compared with 7.4-fold for
wild-type C37). For C37N656D, the presence of AMD3100 did
not alter FI IC50 even at high CoRA concentrations.
Combined, the data suggested that reducing C-peptide-
binding affinity decreased the magnitude of FI-CoRA synergy.
We next asked whether the converse was true. Did increasing
C-peptide affinity result in greater synergistic activity of this
drug combination? We employed two additional C37 variants
with enhanced affinity, C37-KYI (16-fold higher) and di-C37
(greater than 100-fold higher) (38). Against wild-type Env, the
enhanced binding affinity did not translate to higher potency
compared with C37, consistent with a kinetic restriction on
their inhibition (Table 1 and Fig. 3A) (see below and Ref. 38).
Moreover, C37-KYI and di-C37 displayed synergy with
AMD3100 thatmimickedAMD3100/C37 synergy againstwild-
type Env in terms of magnitude and CoRA dependence. By
contrast, the enhancement of FI affinity significantly impacted
inhibition of the V549E Env variant (Table 1 and Fig. 3B). On
the one hand, C37-KYI potency was improved almost 20-fold,
but it still showed the same additive activity as C37 in combi-
nation with AMD3100. On the other hand, di-C37 potency was
improved	100-fold and showed substantial synergy in combi-
nation with the CoRA. In fact, the potency of di-C37 and the
magnitude and CoRA dependence of AMD3100/di-C37 syn-
ergy were nearly identical for the wild-type and the V549E Env
variants. Thus, CoRA/C-peptide synergy was restored for an
Env variant with an affinity-disrupting mutation by sufficiently
dialing up the binding strength of the FI. The data implied that
CoRA/C-peptide synergy required a high-affinity interaction
between the C-peptide and gp41.
Modeling the impact of CoRA on C-peptide inhibition
Our data indicated that the antiviral activity of CoRA/C-pep-
tide combinations depended on the affinity of C-peptide inter-
actions. We previously showed that the factors determining
C-peptide potency differed for high and low-affinity inhibitors.
The discrepancy was best appreciated by modeling intermedi-
ate state inhibition as shown in Fig. 3C. Here, N, I, and F rep-
resent the native, intermediate, and fusogenic conforma-
tions. Fusion inhibitors (X) bind the intermediate state (IX)
and promote transition into an irreversibly deactivated state
(D). Rate constants kf and ks describe the N3 F and IX3 D
transitions, respectively, whereas kon and koff denote inhibi-
tor association and dissociation from gp41. Based on this
model, Equation 4 for fusion inhibitor IC50 was derived (19).
IC50 
kf
kon
1 koffks   kfkon  kfksKD (Eq. 4)
For high-affinity and slowly dissociating FIs (koff 

 ks),
inhibitor binding almost always leads to deactivation. In this
case, inhibitory potency is determined primarily by how fast the
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Figure 2. Combinatorial activities of CoRA AMD3100 and FI C37 against
wild-typeEnvHXB2 and theV549Emutant variant.A, schematic of thegp41
ectodomaindepicting thebinding site for C37 and the relative position of the
V549E substitution. B, AMD3100 titrations of wild-type (black) and V549E
mutant (red) Env. The measured IC50 values were 26 4.1 and 27 6.4 nM,
respectively. C, C37 titration of wild-type (black) and V549E mutant (red) Env
in the absence (filled symbols) and presence (open symbols) of 100 nM
AMD3100. Data have been renormalized to the level of infection in the
absence of C37 and the presence of AMD3100 (if any). D, IC50 values for wild-
type and V549E mutant Env as a function of AMD3100 concentration. Note
that the following data have been repeated in subsequent figures for com-
parativepurposes: AMD3100 titrationofwild-type EnvHXB2 (black squares inB,
repeated in Figs. 4B, 5B, and 7C); C37 titration of wild-type EnvHXB2 (black
squares in C, repeated in Fig. 7D); C37 IC50 values for wild-type EnvHXB2 as a
function of AMD3100 concentration (black squares inD, repeated in Fig. 3A as
green squares and in Fig. 7E as black squares); C37 IC50 values for the V549E
EnvHXB2mutant variant as a function of AMD3100 concentration (red circles
in D, repeated in Fig. 3B as green squares).
Table 1
Inhibitory and binding properties of C37 and 5-Helix FIs
IC50 (upper left) andKD (upper right) values are given in nanomolar concentrations;
kon values (middle right) are in units of M1 s1; and koff values (lower right) are in
units of s1. KD and kon values were measured using an in vitro binding assay
employing the designated C37 and 5-Helix variants (19, 38); these parameters were
used to calculate koff values: koffKD  kon. IC50 values weremeasured for inhibition
of EnvHXB2-mediated HIV-1 infection of U87.CD4.CXCR4 cells performed in this
study. Green boxes indicate FI/Env pairs with kinetically restricted potency (koff

0.2  ks, see text). Red boxes indicate FI/Env pairs with affinity-dependent potency
(koff  5  ks). Yellow boxes indicate FI/Env pairs with potency dependent on both
kinetic and equilibrium factors (koff values within 2-fold of ks). EnvHXB2 ks values,
estimated from a previous study (38), are 4.9 104 s1 for C37 inhibitors and 0.11
s1 for 5-Helix inhibitors. *, nd means not determined.
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inhibitor can associate during the lifetime of the intermediate
state: IC50 kf/kon. This kinetic dependence explains why C37,
C37-KYI, and di-C37 displayed the same potency against wild-
type Env despite having widely varying binding affinities (Fig.
3A). In the proposed mechanism of synergy, CoRAs reduce the
level of coreceptors capable of interacting with Env, thereby
prolonging the intermediate state and increasing the chance of
FI binding gp41.Quantitatively, this proposed effect describes a
decrease in rate constant kf, which, in turn, results in a lower
IC50 value for high-affinity C-peptides.
For low-affinity, rapidly dissociating FIs (koff ks), inhibitor
association is most often followed bymultiple cycles of dissoci-
ation and re-association before Env transitions into the fuso-
genic (F) or deactivated (D) state. Therefore, inhibitory potency
depends upon binding affinity and the relative difference
between the rates to states F andD: IC50 (kf/ks)KD. Thedepen-
dence of potency on binding affinity explains the difference in
IC50 values for C37, C37-KYI, and di-C37 against the V549E
Env variant (Fig. 3B). Our previous work has suggested that the
rates kf and ks for C-peptides share the same dependence on
cellular coreceptor levels (38).3 Thus, adding CoRA should
induce the same fold-reduction in kf and ks, leaving their ratio
unaltered and the IC50 values for the low-affinity, rapidly disso-
ciatingC-peptides unchanged.Hence, we propose that the sim-
ilar dependence of the I3 F and Ix3D transitions on cellular
coreceptor levels leads to additive activity for combinations of
CoRAs and low-affinity C-peptides.
Preservation of CoRA/5-Helix synergy under low-affinity 5-
Helix interactions
Although both C-peptides and 5-Helix target gp41 during
the PHI, our previous work showed that these two inhibitor
classes induced Env deactivation through different mecha-
nisms (38). Notably, the deactivation rate constant ks for 5-He-
lix inhibition did not depend on cellular coreceptor levels.
Therefore, we predicted that CoRA/5-Helix synergy should be
largely independent of 5-Helix-binding affinity. We tested this
prediction using EnvHXB2 variantswithC-HRmutationsN656S
and N656D, which reduced 5-Helix-binding affinity 30- and
5000-fold, respectively (Fig. 4A and Table 1) (38). All three Env
variants showed the same sensitivity to AMD3100, indicating
the C-HR substitutions did not impact CXCR4 utilization of
EnvHXB2 (Fig. 4B). We first used the wild-type version of 5-He-
lix (5HWT), an extremely high-affinity fusion inhibitor with
kinetically restricted potency (IC50  kf/kon) against the wild-
type and N656S Env variants and near kinetically restricted
potency against the N656D Env variant (Table 1 and Fig. 4, C
and E). As expected, the potency of 5HWT was not altered by
affinity-disrupting mutations in the C-HR region. Moreover,
IC50 values for 5HWT decreased upon addition of AMD3100,
consistent with a CoRA-dependent increase in the temporal
exposure of the gp41 C-HR region (Fig. 4E).
Next, we used amutant variant of 5-Helix (5HLAVA) contain-
ing the L556A/V570A dual substitution that reduces the inhib-
itor-binding affinity 13,000-fold (19). 5HLAVA binds relatively
weakly towild-type Env and evenmore poorly to theN656S and
3 It is not known why rate constant ks for C-peptide inhibitors depends upon
chemokine receptor levels on target cells. We have previously speculated
(38) that the IX3D transition follows the same conformational change as
the I3 F transition, except that the attached C-peptide prevents proper
formation of the TOH, leading to irreversible misfolding of the gp41 ect-
odomain. This hypothesis predicts that ks and kf for C-peptide inhibitors
would share the same dependence on target cell chemokine receptor lev-
els, as is observed.
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N656D Env variants (Table 1). Importantly, the rate of 5HLAVA
dissociation from themutant Env variants substantially exceeds
the estimated rate of 5-Helix-induced gp41 deactivation
(koff  ks, see Table 1). As expected for such a low-affinity FI,
5HLAVA potency depended on its binding affinity (IC50  (kf/
ks)KD, see Table 1). The IC50 value was lowest against wild-type
Env (110 nM), higher against the intermediate-affinity variant
N656S Env (1000 nM), and highest against the most affinity-
disrupted variant N656D Env (3000 nM). Despite interacting
with low affinity, 5HLAVA showed synergistic activity against all
three Env variants. Against the wild-type and N656S Env vari-
ants, the magnitude and CoRA dependence of the AMD3100/
5HLAVA synergy closely mimicked those for AMD3100/5HWT
synergy (compare Fig. 4, E and F). The low potency of 5HLAVA
against the N656D Env variant precluded accurate determina-
tion of IC50 values for a similar analysis. However, N656D Env
was substantiallymore sensitive to 1000 nM5HLAVA in the pres-
ence of AMD3100 (50 and 100 nM) than in its absence (Fig. 4G).
Thus, the synergy between AMD3100 and 5-Helix was not sig-
nificantly influenced by 5-Helix-binding affinity, evenwhen the
rate of inhibitor dissociation exceeded the rate of gp41 deacti-
vation. These results were consistent with the 5-Helix-induced
deactivation rate constant ks being independent of coreceptor
levels on target cells.
Impact of kf-altering gp41mutations on CoRA/FI synergy
Certain gp41 mutations can influence the lifetime of the
intermediate state without incurring a substantial disruption to
FI-binding affinity (Fig. 5) (54, 55). The substitution L565Q in
theN-HR elicits a decrease in fusion rate that ismanifested by a
10-fold increase in sensitivity to kinetically restricted FI 5HWT
(Table 1). By contrast, the dual substitution N637K/T639I in
the C-HR enhances fusion rate, resulting in a 10-fold decrease
in 5HWT sensitivity (Table 1). We questioned whether the
effects of these gp41mutations weremediated, in part, through
altered coreceptor interactions and, if so, how that would
impact CoRA/FI synergy. The IC50 values for AMD3100
against L565Q Env and N637K/T639I Env were 63 and 17 nM,
respectively, not substantially different from the 26 nM IC50
value for wild-type Env (Fig. 5B). The data suggested that the
substitutions minimally impacted CXCR4 utilization. The two
mutant Env variants showedAMD3100/5HWT synergy of com-
parable magnitude and CoRA dependence as that for wild-type
Env (Fig. 5C). Similar results were observed for synergy
between AMD3100 and the kinetically restricted FIs di-C37
and PIE12 trimer4 (56) that target the gp41N-HR region (Fig. 5,
D and E). Thus, our data suggested that these gp41 mutations
altered an intrinsic rate of gp41 folding that can be furthermod-
ified extrinsically through coreceptor binding.
Dissecting the dependence of FI/CoRA synergy on coreceptor
binding
Close inspection of our synergy data revealed a tendency for
FI IC50 values to level off at high CoRA concentrations. The
result suggested a limit to the degree that rate constant kf could
be reduced by lowering the levels of available coreceptor on
target cells. Based on this observation, we predicted that the
magnitude of CoRA/FI synergy would be smaller on target cells
expressing lower levels of coreceptor. To test this prediction,
we employed HeLa-derived JC.53 and JC.10 target cells that
4 PIE12 is a D-amino acid peptide selectedbymirror-imagephagedisplay that
binds a hydrophobic pocket at the C terminus of the N-HR coiled coil (56).
In the PIE12 trimer, three PIE12 peptides are cross-linked using polyethyl-
ene glycol linkers to create a molecule capable of multivalent binding to
the gp41 N-HR region exposed during the PHI.
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Figure 4.Maintenance of AMD3100/5-Helix synergy across awide range
of 5-Helix binding affinities. A, schematic of the gp41 ectodomain depict-
ing the 5-Helix-binding site and relative position of the N656S and N656D
substitutions. B, AMD3100 titrations of wild-type (black), N656S (red), and
N656D (green) EnvHXB2 variants. Themeasured IC50 valueswere 264.1, 19
2.9, and 21 5.5 nM, respectively. C and D, 5HWT (C) and 5HLAVA (D) titrations
of theN656S Env variant in the absence (square) andpresence of AMD3100 at
25 (circle), 50 (up triangle), and 100 nM (down triangle). Data have been nor-
malized to the infectivity level in the absence of either inhibitor. E and F, IC50
values for 5HWT (E) and 5HLAVA (F) as a function of AMD3100 concentration for
wild-type (black), N656S (red), and N656D (green) Env. G, relative infectivity
levels of N656Dmutant Env in the absence (square) or presence of AMD3100
at 50 (up triangle) or 100 nM (down triangle) in the presence of the indicated
concentrations of 5HLAVA. Data have been normalized to the level of infectiv-
ity in the presence of AMD3100 and absence of 5HLAVA. Note that the follow-
ing data have been repeated in subsequent figures for comparative purpos-
es: 5HWT IC50 values for wild-type EnvHXB2 as a function of AMD3100
concentration (black squares in E, repeated in Figs. 5C and 7F).
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have similar levels of CD4 (4 105 per cell) but different levels
of CCR5 (1.3  105 and 2.0  103 per cell, respectively) (57).
The IC50 value of CCR5 antagonist TAK-779 against HIV-1
pseudotyped with EnvBaL was lower on target cells expressing
lower CCR5 levels (JC.10), consistent with previous conclu-
sions that CoRAs competitively block chemokine receptor
interactions with Env (Fig. 6A) (35, 39). Furthermore, the IC50
value for kinetically restricted FI C37was significantly lower on
JC.10 cells compared with JC.53 cells, as expected for reduced
CCR5 levels leading to a decreased rate constant kf (Fig. 6B)
(38). As predicted, CoRA/FI synergy differed between the two
cell lines. For cells with high CCR5 levels (JC.53), FI IC50 values
decreased significantly (3–5-fold) in the presence of CoRA (Fig.
6, C and E). By contrast, for target cells with low levels of CCR5
(JC.10), FI IC50 values showed minimal dependence (less than
2-fold) on CoRA concentrations (Fig. 6, D and E). This differ-
ence between cell lines was not dependent on FI target site
(N-HR for C37 and C-HR for 5HWT) andwas observed for both
laboratory-adapted (BaL, H5) and primary isolate (JRFL) Env
strains (Fig. 6, E–H). Thus, FI/CoRA synergy appeared to
require a sufficient level of chemokine receptors on target cells,
below which inhibitor combinations behaved in an additive
manner.
One explanation for these observations is that the coreceptor
binding stoichiometry required for HIV-1 entry is less than the
stoichiometry required to observe CoRA/FI synergy. To test
this conjecture, we investigated the properties of Env trimers
that contained less than three coreceptor-binding sites. We
generated HIV-1 from cells coexpressing wild-type EnvHXB2
(denoted H4) and a variant EnvHXB2 with a V3-loop from the
CCR5-tropic EnvSF162 (denoted H5) (58). The V3-loop swap
rendered H5 Env unable to mediate efficient viral entry on
CXCR4 target cells but capable of mediating robust fusion on
CCR5 cells. Coexpression of the two Env variants resulted in
four trimeric species, (H4)3, (H4)2(H5), (H4)(H5)2, and (H5)3,
with the heterotrimers having amixture of competent CXCR4-
and CCR5-binding sites (Fig. 7A). To specifically focus on het-
erotrimer activity, H4/H5 expression was biased 1:19, and the
resulting HIV-1 sample was applied to CXCR4 cells (Fig. 7B).
With this expression ratio, the predominant trimeric species,
homotrimer (H5)3, lacked a CXCR4-binding site and was not
fusogenic. The other homotrimer, (H4)3, was fusogenic but
formedonly aminiscule fraction of total Env trimers. The infec-
tivity of this viral sample far exceeded the level predicted if only
homotrimeric (H4)3 contributed tomembrane fusion (Fig. 7B).
The result suggested that the heterotrimeric Envs containing
either one or two CXCR4-binding sites were the predominant
fusogenic species in this viral population.
HIV-1 pseudotyped with H4/H5  1:19 displayed signifi-
cantly higher sensitivity to both AMD3100 and C37 compared
HIV-1 pseudotyped with (H4)3 homotrimers alone (Fig. 7, C
and D). The results confirmed that Env heterotrimers contrib-
uted the majority of fusogenic activity in these mixed trimer
viral samples. The enhanced sensitivity to AMD3100 likely
reflected an increased requirement forCXCR4on target cells to
compensate for a reduced number of coreceptor-binding sites
on fusogenic Env heterotrimers. The enhanced sensitivity to
C37 probably resulted from slower fusion kinetics due to
reduced coreceptor binding (similar to the impact of decreasing
coreceptor levels on target cells). Notably, C37 IC50 for HIV-1
pseudotyped with H4/H5  1:19 showed no dependence on
AMD3100 concentration (Fig. 7E). Likewise, 5HWT IC50
against this viral population was minimally perturbed in the
presence of AMD3100 (Fig. 7F). The results were in sharp con-
trast to the CoRA/FI synergy seen for HIV-1 pseudotyped with
(H4)3 homotrimers.
We repeated these experiments biasing H4/H5 expression
19:1 and using CCR5 target cells (Fig. 8A). Again, the infectiv-
ity of viral samples containingmixed Env trimers exceeded that
predicted if only (H5)3 homotrimers contributed to viral entry
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Figure 5. Impact of rate-altering gp41 mutations on CoRA/FI synergy. A, schematic of the gp41 ectodomain depicting the di-C37-, PIE12 trimer-, and
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(Fig. 8B). Although expression of mixed trimers did not impact
TAK-779 sensitivity, HIV-1 containing heterotrimers was
much more sensitive to FI than HIV-1 expressing only (H5)3
homotrimers (Fig. 8, C andD). As before, the CoRA/FI synergy
observed for (H5)3 homotrimers was largely absent when het-
erotrimers were the predominant fusogenic Env species (Fig. 8,
E and F). Thus, regardless of which chemokine receptor was
used for entry, reducing the number of coreceptor-binding sites
on the Env trimer appeared to ablate the CoRA/FI synergy. The
data supported our conjecture that CoRA/FI synergy required
multiple coreceptor binding events that exceeded the number
required for viral entry.
Discussion
Synergistic drug combinations provide opportunities for
therapeutic augmentation without requiring dose escalations
that increase both cost and potential toxicity risks. Synergistic
activity arises from drug interactions that can occur at micro-
scopic to macroscopic scales, ranging from a single macromol-
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Figure 7. Impact of modifying the number of CXCR4-binding sites per
EnvHXB2 trimer on CoRA/FI synergy. A, mixed trimer population resulting
from the coexpresssion of Env variants H4 (HXB2) and H5 in virus-producing
cells. Each of the four possible trimeric species has a different number of
competent CXCR4-binding sites (#). The fraction of each trimeric species
expressed in the entire HIV-1 sample is listed for H4/H5 expression ratios 1:0,
1:19, and 0:1. Numbers in the 1:19 column reflect binomial probabilities that
assume random assortment of individual protomers into the designated
trimer.B, relative infectivities of the 1:0, 1:19, and0:1HIV-1 samples applied to
U87.CD4.CXCR4 target cells. Viral input was normalized to p24 content of
each sample. Thedotted lines in the 1:19 viral data reflect the relative fractions
of the trimeric species plotted on the same relative infectivity scale (blue,
(H5)3; green, (H5)2(H4); cyan, (H5)(H4)2; and black, (H4)3). The red line in the 0:1
viral data reflects the detection limit for viral infection in this set of experi-
ments. TheWesternblots show the total expressionof gp160 (*) andgp41 (**)
in HIV-1-producing cells expressing H4/H5 at the ratios indicated on the axis
of the plot above. The numbers to the left reflect molecular mass standards in
kDa.C andD, titrations of AMD3100 (C) andC37 (D) against the 1:0 (black) and
1:19 (red) viral samples. The AMD3100 IC50 values were 26  4.1 and 7.1 
0.77 nM, respectively. The C37 IC50 values were 2.8 0.27 and 0.70 0.16 nM,
respectively. E and F, IC50 values for C37 (E) and 5HWT (F) as a function of
AMD3100 concentration for the two HIV-1 samples.
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ecule (e.g. cooperative binding through allostery), to the cell or
tissue level (e.g. coordinated disruption of multi-protein signal-
ing pathway), and to the whole organism (e.g. enhanced bio-
availability of an active drug due to reduced in vivo clearance
caused by a second drug) (59). Mechanistic studies of drug
combinations can provide detailed insights into complex mul-
tistep biochemical processes. Here, we dissected the compli-
cated synergy profile of two classes of HIV-1 entry inhibitors,
CoRAs that block gp120–chemokine receptor interactions and
FIs that disrupt conformational transitions in gp41. The data
supported the proposedmodel that synergy for these inhibitors
reflects kinetic properties of Env conformational changes.
However, our results showed an unanticipated dependence of
synergy on coreceptor-binding stoichiometry and FI-binding
affinity.
In previous drug combination studies employing molecules
that disrupt gp120–coreceptor interactions and C-peptide
T20, synergy was not consistently observed (31, 43–47). Our
findings pointed to several possible explanations for this var-
iability. First, we showed that CoRA/FI synergy critically
depended on levels of chemokine receptors on target cells, and
below some threshold, CoRAs and FIs interacted additively.
Discrepancies in chemokine receptor level among different cell
lines or among PBMC donors could account for the variance
between studies. Second, we demonstrated that the magnitude
of synergy between CoRAs and C-peptides like T20 depended
on C-peptide-binding affinity, with maximal synergy observed
for very high-affinity C-peptide variants, whereasmere additiv-
ity was measured for low-affinity C-peptide variants. With T20
having only a modest affinity for gp41 (52), discrepancies in the
N-HR sequences of Envs used in different studies could be a
source of variability. Finally, we determined that the number of
coreceptor binding events required for CoRA/FI synergy
exceeded the number required for HIV-1 entry. As differences
in gp120-chemokine receptor affinity could alter the corecep-
tor stoichiometry required for entry, we hypothesize that gp120
sequence variation among Envs used in these studies could
impact the level of observed synergy. Further work will be
needed to test this conjecture, but the mechanism might be
particularly relevant for understanding the wide variety of syn-
ergy profiles for clinical HIV-1 isolates in the aforementioned
SCH-C/T20 combination study (47).
Our results showed that the level of C37 resistance conferred
by the V549E substitution depended on CoRA concentration.
The V549E mutation reduced C37 potency 100-fold in the
absence of CoRA and 750-fold in the presence of 100 nM
AMD3100 (Fig. 2D). The result was surprising because the
escape mutation influenced FI interaction independently of
coreceptor binding. The impact of CoRAs on C37 resistance
was traced to disparities in the biophysical determinants of
potency for high- and low-affinity FIs (as distinguished by their
rates of dissociation relative to the rate of gp41 deactivation).
Although the IC50 values for high-affinity (slowly dissociating)
FIs depended upon the I 3 F transition rate (kf, see Fig. 3C),
IC50 values of low-affinity (rapidly dissociating) FIs depended
upon the ratio of the I3 F and IX3D transition rates (kf/ks). FI
potency was enhanced by a CoRA-dependent decrease in kf.
However, that effect wasmitigated for low-affinity C37 variants
because both kf and ks have the same dependence on target-cell
coreceptor levels for inhibitors targeting the gp41 N-HR. This
switch in determinants for C37 potency accounted for the loss
of CoRA/FI synergy in the setting of affinity-disrupting escape
mutations. This loss nullifies a potentially important benefit of
synergistic antiviral combinations, specifically the possibility
that inhibitor concentrations might be maintained in a useful
therapeutic window even when resistance mutations would
render one inhibitor poorly efficacious in the absence of a syn-
ergistic partner. Curiously, CoRA/FI synergy persisted for low-
affinity 5-Helix variants. The results reinforced the idea that
N-HR-targeted andC-HR-targeted FIs trigger irreversible gp41
deactivation (IX3 D transition) through very different mech-
anisms (38).
In addition to gp120-coreceptor interactions, substitutions
in the gp41 N-HR and C-HR regions can influence the lifetime
of the PHI (54, 55). How such mutations impact the fusion
Figure 8. Impact of modifying the number of CCR5-binding sites per
EnvH5 trimeronCoRA/FI synergy.Data arepresentedas in Fig. 7 except that
the experiments utilized U87.CD4.CCR5 cells, TAK-779 as the CoRA, and an
H4/H5 expression ratio of 19:1 for the viral sample with mixed Env trimers. A,
the number of CCR5-binding sites (column #) and relative population of each
trimer species. B, infectivities of the 1:0, 19:1, and 0:1 HIV-1 samples and Env
expression levels in virus-producing cells. C and D, titrations of TAK-779 (C)
and C37 (D) against the 1:0 (black) and 19:1 (red) viral samples. TAK-779 IC50
values were 17  4.5 and 27  6.2 nM, respectively. C37 IC50 values in the
absence of CoRA were 7.9 2.6 and 1.0 0.32 nM, respectively. E and F, IC50
values for C37 (E) and 5HWT (F) as a function of TAK779 concentration for the
two HIV-1 samples.
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rate is not known. Given the packing of gp120 around gp41 in
the native state (and possibly the PHI (58)), it is formally possi-
ble that gp41 substitutions could exert effects on gp120 struc-
ture and indirectly alter coreceptor utilization by Env. In this
study, the kf-altering substitutions L565Q and N637K/T639I
did not have a large impact on CoRA potency. Furthermore,
both the slower and faster Env variants showed the same syn-
ergy profile (both in magnitude and concentration depen-
dence) as wild-type Env. Together, the data suggested that
these gp41 substitutions exertedminimal impact on coreceptor
utilization by Env. Instead, the results implied that the gp41
sequence sets a basal lifetime for the PHI (observed at high
CoRA concentrations) that can be shortened by excess core-
ceptor binding.
Our findings also offered insights into the timing of corecep-
tor binding events coordinating Env conformational changes.
In one model of HIV-1 entry, CD4 binding to the native state
drives Env into the PHI, whereas coreceptor binding during the
PHI triggers collapse into the TOH (60). This model explained
how coreceptor levels on target cells influence PHI lifetime and
FI potency. In support of this model, soluble CD4 (sCD4) alone
was shown to be sufficient to trigger Env to expose FI-binding
sites in gp41 pulldown and Env-mediated membrane fusion
assays (of note, these studies employed laboratory-adapted Env
strains prone to rapid and efficient sCD4-induced gp120 shed-
ding) (17, 18, 20, 61, 62). However, the model failed to explain
the difference between CoRAs and FIs observed in time-of-
addition assays (37, 39). In these studies, escape from CoRA
inhibition occurred considerably before escape from FI inhibi-
tion, implying that coreceptor binding significantly preceded
collapse into the TOH. Our results showing an absence of
CoRA/FI synergy at low coreceptor-binding stoichiometry sug-
gested a solution to this inconsistency; the first coreceptor-
binding event precedes and facilitates transformation into the
PHI, whereas subsequent coreceptor binding events during the
PHI promote collapse into the TOH. Only the first coreceptor
binding event is absolutely required for HIV-1 entry, whereas
subsequent binding events primarily modulate the rate of
fusion. Env species mediating fusion meet only the minimal
coreceptor-binding requirement when coreceptor levels on
target cells are low or Env trimers contain one functional core-
ceptor-binding site. Because Env does not interact with addi-
tional coreceptors, the PHI lifetime remains unmodulated, and
FI potency becomes CoRA independent.
Based on the functionality of H4/H5 mixtures, our model
currently assumes that a single coreceptor binding event is suf-
ficient to drive transformation into the PHI. However, the
model would remain valid if two coreceptor binding events
were required to facilitate this transition, and only the third
modulated the PHI lifetime. Indeed, results from this study sug-
gest that different Env strains may have different coreceptor-
binding requirements for entry (e.g. compare the fusogenic
activities of HIV-1 pseudotyped with H4/H5 mixtures in Figs.
7B and 8B). Future work with better defined Env heterotrimers
will be needed to piece together the exact stoichiometries of
coreceptor binding that facilitate the transition of Env into the
PHI and, ultimately, the TOH.
Experimental procedures
Cell lines and reagents
The following cell lines and reagents were obtained through
theAIDSResearch andReferenceReagent Program,Division of
AIDS, NIAID, National Institutes of Health: U87.CD4.CXCR4
and U87.CD4.CCR5 cells from Drs. HongKui Deng and Dan
Littman (63); Chessie 8 hybridoma fromDr. George Lewis (64);
maraviroc (11580) (65, 66); AMD-3100 (67, 68); and TAK779
(69). HEK 293T cells were obtained from the ATCC. JC.53 and
JC.10 cells were kindly provided by Dr. David Kabat (Oregon
Health Sciences University) (57). PIE12 fusion inhibitors were
kindly provided by Dr. Michael Kay (University of Utah) (56).
Fusion inhibitor preparation
C-peptide T20 was synthesized using standard Fmoc (N-(9-
fluorenyl)methoxycarbonyl) chemistry by the Peptide Synthe-
sis Facility at the Sidney Kimmel Cancer Center, Thomas Jef-
ferson University. Cleaved, desalted peptides were purified to
homogeneity by reverse phase-HPLC using a Vydac C18 col-
umn and a linear gradient of acetonitrile in water containing
0.1% trifluoroacetic acid. C-peptide C37 and its variants were
prepared from a recombinant gp41 TOH construct NC1 as
described previously (28, 38). Briefly, NC1 was recombinantly
expressed and purified from bacterial lysates by metal-chelate
chromatography and subsequently subjected to trypsin
digestion to cleave C37 from the N-HR peptide N40. C37 was
purified to homogeneity using reverse phase-HPLC as
described above. Di-C37 is a dimerized form of C37 con-
nected via an engineered disulfide bond at the C terminus of
each monomer (38).
5-Helix proteins contain three N40 segments and two C37
segments alternately connected by short linkers into a single
polypeptide (28). The proteins were recombinantly expressed
and purified as described previously (19). Briefly, 5-Helix was
solubilized from bacterial inclusion bodies using 8 M guanidine
HCl inTris-buffered saline (TBS), loaded onto nickel-nitrilotri-
acetic acid-agarose beads (Qiagen), and renatured in 4 M gua-
nidine HCl by a reverse thermal gradient (90 °C to room tem-
perature over 4 h). Aggregates were separated from properly
folded protein by size-exclusion chromatography (Superdex 75,
GE Healthcare).
The concentrations of T20, PIE12 trimer, C37 peptides, and
5-Helix proteins were determined by absorbance at 280 nm by
the method of Edelhoch (70). The interaction and inhibition
properties of these inhibitors have been extensively character-
ized (19, 38, 52, 56).
HIV-1 production and characterization
HIV-1 particles were prepared from 293T cells (5  106)
transfected (X-tremeGENE, Roche Applied Science) with 2.5
g of Env-deficient HIV-1NL4-3 genome pNL4-3RELuc
(71) and 2.5 g (total) of one or two Env-expressing plasmids
(pEBB_EnvX, X  HXB2, JR-FL, BaL, and H5). EnvH5 is an
EnvHXB2 variant with a V3 loop derived from CCR5-tropic
EnvSF162 (58). Virus-containing supernatants were harvested
48 h post-transfection and were used fresh for infectivity stud-
ies described below. Virus-producing cells were lysed and ana-
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lyzed byWestern blotting for expression of Env. Briefly, lysates
were clarified by centrifugation, and the protein contents of the
supernatants were determined by Bradford analysis (Thermo
Fisher Scientific). Lysate aliquots normalized by protein con-
tent were separated by SDS-PAGE (10%), transferred to nitro-
cellulose paper (GE Healthcare), and probed with monoclonal
antibody Chessie 8, which recognizes an epitope in the gp160
and gp41 cytoplasmic tail (64). Western blottings were devel-
oped with an HRP-conjugated secondary antibody (Jackson
ImmunoResearch) and ECL reagent kit (Pierce).
HIV-1 infection was measured on U87 cells, except as noted
in Fig. 6. Cells were plated at a density of 20,000 per well in
48-well plates 18–24 h prior to infection. On the day of infec-
tion, media were replaced with HIV-1-containing supernatant
(see above) and freshmedia containing one or two inhibitors as
indicated. After 36–48 h, the cells were lysed in 1% Triton
X-100, and levels of the luciferase reporter were assessed by
luminescence (Promega or Pierce). To measure fusogenic
activities of HIV-1 particles pseudotyped with Env strain H4,
H5, or a mixture of H4 and H5 (Figs. 7B and 8B), luciferase
activity was normalized to p24 content of the viral sample
determined by ELISA (Aalto, Ireland).
Inhibitor titrations of viral infection were fit to the simple
dose-response Langmuir equation (Equation 1) to extract IC50
values. This choice was supported by the observation that the
vast majority of titrations (97%) fit to the Hill equation with a
Hill coefficient nH between 0.9 and 1.1.
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